Medtronic plc announced that the Centers for Medicare & Medicaid Services $(CMS)$ has finalized a National Coverage Determination (NCD) for the Medtronic Symplicity Spyral™ renal denervation $(RDN)$ system. This decision grants Medicare coverage for the Symplicity blood pressure procedure, enabling qualifying patients with uncontrolled hypertension to access this minimally invasive therapy. The coverage determination represents a significant milestone for Medtronic, expanding patient access and accelerating adoption of the technology in major U.S. medical centers. The Symplicity Spyral RDN system is now approved for commercial use in nearly 80 countries worldwide.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: CG09695) on October 28, 2025, and is solely responsible for the information contained therein.